0001493152-26-022614
SEC filingQ1 FY2026 marked Abeona’s first full quarter of ZEVASKYN® commercial sales, generating $8.7M in revenue — but operating and net losses widened significantly year-over-year as commercialization investments outpaced early adoption.
Q1 FY2026 represents Abeona’s inaugural quarter of revenue generation for ZEVASKYN®, following its FDA approval in April 2025. The $8.7M in revenue reflects initial distribution through ZEVASKYN®-qualified treatment centers and confirms the transition from development to commercial operations. Gross profit of $6.0M — a 69.1% gross margin — underscores the product’s favorable cost structure, supported by in-house manufacturing at the company’s Cleveland cGMP facility.
Net income totaled -$17.1M, a 41.9% decline year-over-year. This reflects not only the expanded operating loss but also non-operating factors, including gains on the fair value of warrant liabilities. Management attributes those gains to both the decrease in Abeona’s stock price over the quarter and the shortened remaining term of outstanding warrants — a recurring dynamic in companies with significant warrant exposure.
Net cash used in operating activities was -$19.8M, closely tracking the net loss and confirming the absence of meaningful working capital inflection points this early in commercialization. Capital expenditures fell to $935K from $1.4M in Q1 FY2025 — consistent with the reclassification of production costs into inventory rather than R&D, per FDA approval. Free cash flow totaled -$20.7M. While this level of outflow is expected during launch, management reaffirms that continued negative cash flows will persist until ZEVASKYN® achieves broader treatment center adoption and revenue scale — a trajectory explicitly outlined in the outlook context.
Abeona’s principal source of liquidity remains cash, cash equivalents, restricted cash, and short-term investments. Management cautions that without additional financing or material increases in license or product revenue, insufficient capital resources could materially impair future prospects — a risk inherent in the prolonged commercial ramp-up phase for novel therapies.